What is the appropriate starting dose of compounded testosterone for a postmenopausal woman (age 45‑60) without estrogen‑dependent breast cancer, uncontrolled hypertension, liver disease, or elevated hematocrit?

Compounded Testosterone Dosing for Postmenopausal Women

Compounded testosterone preparations cannot be recommended for postmenopausal women due to lack of efficacy and safety data, and you should instead use approved formulations dosed to achieve physiological premenopausal testosterone concentrations (approximately 20-80 ng/dL total testosterone). 1

Critical Guideline Position on Compounded Preparations

The 2019 Global Consensus Statement explicitly states that compounded "bioidentical" testosterone therapy cannot be recommended for treatment of hypoactive sexual desire disorder (HSDD) because of the lack of evidence for efficacy and safety 1. This is the highest-quality, most recent guideline available and directly addresses your question.

However, the guideline acknowledges reality: if an approved product is unavailable, compounded products may be used only if:

• The compounding pharmacy complies with Active Pharmaceutical Ingredient purity standards and Good Manufacturing Practice
• Dosing is limited to achieving testosterone concentrations in the physiologic premenopausal range 1

Specific Dosing Targets

Target Testosterone Levels

When compounded testosterone must be used, aim for:

• Total testosterone: 20-80 ng/dL (based on premenopausal physiological range) 2, 3
• Free testosterone: approximately 5-12 pg/mL 2

Practical Starting Doses from Research

Research on transdermal testosterone gel in postmenopausal women provides concrete dosing guidance:

• 4.4 mg daily transdermal testosterone raised average steady-state total testosterone to mid-to-high normal premenopausal range (approximately 50-60 ng/dL) 2
• 10 mg daily of 1% testosterone gel achieved mean testosterone levels of 3.2 nmol/L (approximately 92 ng/dL) 4
• Higher doses (8.8-13.2 mg daily) consistently produced supraphysiological levels and are not recommended 2

For compounded transdermal preparations, start with approximately 5 mg daily of testosterone (as a 1% gel or cream) applied to shoulders and upper arms 4, 2. This approximates the 4.4 mg dose that achieved physiological levels in controlled studies.

Monitoring Algorithm

Baseline (Before Starting)

• Measure total testosterone using liquid chromatography-tandem mass spectrometry (LC-MS/MS) if available 1
• Document sexual function using validated instruments
• Check hematocrit, lipid panel, liver function

Follow-up Schedule

1. 3-6 weeks after initiation: Repeat total testosterone to ensure levels are in physiological premenopausal range (20-80 ng/dL) 1
2. Every 6 months:
   • Total testosterone level to screen for overuse 1
   • Assess for androgenic side effects (acne, hirsutism)
   • Monitor hematocrit (though increases are minimal with physiological dosing) 1

Decision Points

• If no benefit by 6 months: Cease treatment 1
• If testosterone >100 ng/dL: Reduce dose
• If androgenic side effects develop: Reduce dose or discontinue

Critical Caveats

What NOT to Use

Avoid these formulations entirely as they produce supraphysiological levels:

• Testosterone pellets 1
• Testosterone injections 1
• Any preparation resulting in testosterone >100 ng/dL

Route of Administration Matters

• Transdermal preparations (gels, creams, patches) are preferred as they maintain more stable physiological levels 2, 5
• Intramuscular injections cause fluctuating supraphysiological peaks and are not recommended for women 1, 5

Safety Data Limitations

Safety data for testosterone therapy in women extend only to 24 months 1, 6. Long-term cardiovascular, cancer, and cognitive safety data are lacking 5. This must be discussed with patients.

The Estrogen Question

Concurrent estrogen therapy does not significantly affect testosterone pharmacokinetics over short durations 2, so the same dosing applies whether the patient is on estrogen or not.

Evidence Quality Note

The 2019 Global Consensus Statement represents Level I, Grade A evidence for testosterone efficacy in postmenopausal women with HSDD when dosed physiologically 1. However, this evidence applies to approved formulations studied in clinical trials, not compounded preparations. The recommendation against compounded products is based on Expert Opinion due to insufficient data 1.

The 2014 Endocrine Society guideline similarly recommends against compounded preparations and male formulations due to lack of safety and efficacy data in women 6.

Bottom line: If you must use a compounded preparation, start with 5 mg daily transdermal testosterone, measure levels at 3-6 weeks, and titrate to achieve 20-80 ng/dL total testosterone while monitoring closely for adverse effects.